“We look forward to the more frequent interactions with the Agency that the Fast Track designation provides, as we prepare for the NDA filing,” said Rosty Raykov, CEO of Fennec. The Fast Track designation means that Pedmark may be eligible for Priority Review once the Company submits a New Drug Application.

There are currently no drugs approved for the prevention of platinum-induced ototoxicity.